ONTX - オンコノバ・セラピュ―ティクス (Onconova Therapeutics Inc.) オンコノバ・セラピュ―ティクス

 ONTXのチャート


 ONTXの企業情報

symbol ONTx
会社名 Onconova Therapeutics Inc (オンコノバ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 オンコノヴァ・セラピューティクス(Onconova Therapeutics Inc.)は臨床段階のバイオ医薬品会社であり、がん治療用の小分子薬剤候補の発見・開発に取り組む。同社が作成した標的抗がん剤は、がんを促進する特定の細胞経路に対して機能するように設計される。同社は3つの臨床段階の製品候補と6つの前臨床プログラムを有する。同社の前臨床パイプラインはキナーゼ、細胞代謝や分裂を標的にする6つのプログラムを含む。   オンコノバ・セラピュ―ティクスは米国のバイオテクノロジ―会社。がん治療の小分子医薬品候補の発見と開発に従事する。主に臨床期向け治療薬の開発に注力。臨床検査段階の治療薬候補には、骨髄異形成症候群および頭頚部がん用の「リゴサチブ」、急性放射線症候群用の「recilisib」などがある。   Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.
本社所在地 375 Pheasant Run Newtown PA 18940 USA
代表者氏名 Michael M. B Hoffman マイケル・M・ホフマン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 267-759-3681
設立年月日 36130
市場名 NASDAQ Small Cap
ipoyear 2013年
従業員数 36人
url www.onconova.com
nasdaq_url https://www.nasdaq.com/symbol/ontx
adr_tso
EBITDA EBITDA(百万ドル) -24.34600
終値(lastsale) 5.92
時価総額(marketcap) 33590944.32
時価総額 時価総額(百万ドル) 33.76100
売上高 売上高(百万ドル) 1.30200
企業価値(EV) 企業価値(EV)(百万ドル) 4.22100
当期純利益 当期純利益(百万ドル) -22.85700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Onconova Therapeutics Inc revenues increased 96% to $1M. Net loss decreased 12% to $9.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other income net increase from $11K to $112K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$22.78 to -$6.14.

 ONTXのテクニカル分析


 ONTXのニュース

   Onconova Therapeutics to Provide Corporate Update and Announce First Quarter Financial Results on May 11, 2022  2022/05/04 20:05:00 Benzinga
NEWTOWN, Pa., May 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX ), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its first quarter 2022 financial results on Wednesday, May 11, 2022. Management plans to host a conference call and live webcast at 4:30 p.m. ET on the same day to discuss these results and provide an update on its pipeline programs. Conference Call and Webcast Information Interested parties who wish to participate in the conference call may do so by … Full story available on Benzinga.com
   Onconova Therapeutics, Inc. Sees Large Decline in Short Interest  2022/05/02 05:49:12 Business Mag
Onconova Therapeutics, Inc. was the target of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 52,500…
   Volume - Onconova Therapeutics, Inc. Sees Large Decline in Short Interest  2022/05/02 05:49:12 Business Mag
Onconova Therapeutics, Inc. was the target of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 52,500…
   Onconova Therapeutics Announces Acceptance of Abstract for Publication at the ASCO Annual Meeting  2022/04/27 14:16:59 Benzinga
NEWTOWN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX ), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the acceptance of an abstract for publication at the American Society of Clinical Oncology (ASCO) Annual Meeting. Details on the abstract are provided below. Abstract Title: Narazaciclib''s kinase inhibitory activity is differentiated from approved CDK4/6 inhibitors in preclinical models Abstract Number: e15096 Publication Date and Time: May 26, 2022, at 5:00 p.m. ET About Onconova Therapeutics Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova''s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and …
   Onconova Therapeutics shares fall after wider-than-expected FY loss  2022/03/18 17:06:12 Seeking Alpha
Onconova Therapeutics <> shares fall -4.51% after the company reported wider-than-expected gaap loss per share for FY 2021 after markets closed on Thursday. The company reported…
   Onconova Therapeutics (ONTX) Investor Presentation IP - Slideshow  2022/02/11 08:35:31 Seeking Alpha
   Onconova Therapeutics Inc Shares Near 52-Week Low - Market Mover  2022/01/15 14:05:20 Kwhen Finance
Onconova Therapeutics Inc (ONTX) shares closed today at 5.2% above its 52 week low of $2.11, giving the company a market cap of $47M. The stock is currently down 12.9% year-to-date, down 79.3% over the past 12 months, and down 99.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 51.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 2.3% lower than its 5-day moving average, 12.1% lower than its 20-day moving average, and 34.5% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 43.2% The company's stock price performance over the past 12 months lags the peer average by 74.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Onconova Therapeutics Inc Shares Near 52-Week Low - Market Mover  2022/01/14 05:11:52 Kwhen Finance
Onconova Therapeutics Inc (ONTX) shares closed today at 0.5% above its 52 week low of $2.22, giving the company a market cap of $48M. The stock is currently down 11.8% year-to-date, down 78.4% over the past 12 months, and down 99.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 7.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 71.4% The company's stock price performance over the past 12 months lags the peer average by 74.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Onconova Therapeutics Inc Shares Near 52-Week Low - Market Mover  2022/01/09 14:42:43 Kwhen Finance
Onconova Therapeutics Inc (ONTX) shares closed today at 0.9% above its 52 week low of $2.28, giving the company a market cap of $49M. The stock is currently down 9.8% year-to-date, down 75.8% over the past 12 months, and down 99.6% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 44.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 91.8% The company's stock price performance over the past 12 months lags the peer average by 70.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Onconova Therapeutics Inc Shares Close in on 52-Week Low - Market Mover  2022/01/07 11:47:30 Kwhen Finance
Onconova Therapeutics Inc (ONTX) shares closed today at 1.3% above its 52 week low of $2.34, giving the company a market cap of $50M. The stock is currently down 7.5% year-to-date, down 81.0% over the past 12 months, and down 99.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 9.0% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 146.2% The company's stock price performance over the past 12 months lags the peer average by 96.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Recessive Dystrophic Epidermolysis Market Dynamic Expansion in Clinical Research with Phoenix Tissue Repair, Onconova Therapeutics, Fibrocell Technologies, Holostem Terapie Avanzate, Wings Therapeutics Inc.  2021/08/27 10:23:19 OpenPR
Recessive dystrophic epidermolysis bullosa severe generalized (RDEB-sev gen) is the classic form of the condition and is the most severe. Affected infants are typically born with widespread blistering and areas of missing skin, often caused by trauma that occurs during
   Onconova Therapeutics EPS beats by $0.01, beats on revenue  2021/08/12 20:07:21 Seeking Alpha
   Bright Stock Buzz: Sunworks, Inc. (NASDAQ:SUNW), Onconova Therapeutics, Inc. (NASDAQ:ONTX)  2021/08/09 21:49:55 Stock Equity
Sunworks, Inc. (SUNW) with the stream of 7.17% also noticed, India Onconova Therapeutics, Inc. (ONTX) encountered a rapid change of 2.34% in the last hour of Mondays trading session. Sunworks, The post Bright Stock Buzz: Sunworks, Inc. (NASDAQ:SUNW), Onconova Therapeutics, Inc. (NASDAQ:ONTX) appeared first on Stocks Equity .
   Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2021 Financial Results on August 12, 2021  2021/08/05 12:00:00 Intrado Digital Media
Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 12. Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 12.
   Hillcrest Wealth Advisors - NY, LLC Buys iShares Core S&P Small-Cap ETF, iShares MSCI ...  2021/08/03 16:38:28 GuruFocus
Related Stocks: GOOGL , XLF , AAPL , IJR , EEM , BND , MSFT , GOOG , 0T2 , BA , JNK , FB , XLU , ONTX , D ,

 関連キーワード  (医薬品 米国株 オンコノバ・セラピュ―ティクス ONTX Onconova Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)